Similar companies
Company | Transaction Value | |
---|---|---|
OcugenOCGN |
-$4.6M | |
AmarinAMRN |
$1.7M | |
Gilead SciencesGILD |
-$254M | |
Anavex Life SciencesAVXL |
-$14M | |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
Name | Transaction Date | Sold / Bought | Shares | Price | Value |
---|---|---|---|---|---|
Nirland Ltd | Oct 7, 2024 | Sell | 939,009 | $0.1028 | $97,000 |
Nirland Ltd | Oct 4, 2024 | Sell | 1,368,991 | $0.1026 | $140,000 |
Nirland Ltd | Oct 3, 2024 | Sell | 1,500,000 | $0.1043 | $160,000 |
Nirland Ltd | Oct 2, 2024 | Sell | 333,177 | $0.1028 | $34,000 |
Nirland Ltd | Oct 1, 2024 | Sell | 1,250,000 | $0.1131 | $140,000 |
Nirland Ltd | Sep 30, 2024 | Sell | 1,016,823 | $0.12 | $120,000 |
Corvus Capital Ltd. | Jul 17, 2024 | Sell | 1,514,100 | $0.2583 | $390,000 |
Corvus Capital Ltd. | Jul 16, 2024 | Sell | 10,244,392 | $0.3169 | $3.2M |
Corvus Capital Ltd. | Jul 15, 2024 | Sell | 1,005,200 | $0.2471 | $250,000 |
Corvus Capital Ltd. | Jul 12, 2024 | Sell | 1,389,820 | $0.2471 | $340,000 |
Corvus Capital Ltd. | Jul 11, 2024 | Sell | 582,952 | $0.2972 | $170,000 |
Corvus Capital Ltd. | Jul 11, 2024 | Sell | 300,000 | $0.29 | $87,000 |
Corvus Capital Ltd. | Jul 10, 2024 | Sell | 150,000 | $0.3338 | $50,000 |
Corvus Capital Ltd. | Jul 9, 2024 | Sell | 77,681 | $0.4358 | $34,000 |
Corvus Capital Ltd. | Jul 8, 2024 | Sell | 35,923 | $0.51 | $18,000 |
Corvus Capital Ltd. | Jul 3, 2024 | Sell | 1,000 | $0.64 | $640 |
Farley Chele Chiavacci | Apr 22, 2024 | Buy | 200,332 | $0 | $0 |
Tapolczay David | Apr 22, 2024 | Sell | 200,332 | $0 | $0 |
What's the latest insider transaction for Conduit Pharmaceuticals?
The most recent insider transaction for Conduit Pharmaceuticals was conducted by Nirland Ltd, who sold 939,009 shares on October 7, 2024 at a price of $0.10 per share.
Which insider has sold the most CDT stock over the last two years?
Corvus Capital Ltd. has sold the most CDT stock in the last 2 years, with a total value of $4.6M.
What is the total value of insider transactions for Conduit Pharmaceuticals (CDT) in the last 2 years?
The total value of insider transactions for Conduit Pharmaceuticals in the last 2 years is negative, amounting to -$5.3M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Conduit Pharmaceuticals' market confidence?
Over the last 2 years, insider transactions for Conduit Pharmaceuticals have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.